Stocks and InvestingStocks and Investing
Thu, March 10, 2022
Wed, March 9, 2022
Tue, March 8, 2022
Mon, March 7, 2022

Matthew Harrison Maintained (SRPT) at Hold with Increased Target to $80 on, Mar 7th, 2022


Published on 2024-10-27 19:59:09 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $71 to $80 on, Mar 7th, 2022.

Matthew has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Matthew


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $105 on, Thursday, March 3rd, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $150 on, Wednesday, March 2nd, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $150 on, Wednesday, January 5th, 2022
  • Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $125 on, Thursday, December 9th, 2021